Results: After 48 weeks of therapy, serum HBV DNA levels decreased with a median 4.07±2.47 log10 copies/mL. Twenty-three(11.2%) of patients had ER. Twenty-six (12.7%) patients achieved HBeAg seroconversion. HBV DNA <4 log 10 copies/mL at week 4 predict both ER and HBeAg seroconversion. HBV DNA> 4log10 copies/mL at 4 weeks but decline to <4log10 copies/mL at 12 weeks or 24 weeks both can predict ER and HBeAg seroconversion. Less than 2 log 10 HBV DNA reductions at 24 weeks might predict NR.